PTC Therapeutics Inc.
PTCT | NASDAQ
$65.26
-$0.11 (-0.17%)
At close: Sep 21, 2026, 4:00 PM ET
$73.46
+$8.20 (+12.57%)
Pre-market:
Sep 22, 2026, 8:24 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.73B | 806.78M | 937.82M | 698.8M | 538.59M | 380.77M |
Cost of Revenue | 71.76M | 57.4M | 65.49M | 44.68M | 32.33M | 18.94M |
Gross Profit | 1.66B | 749.38M | 872.34M | 654.12M | 506.27M | 361.82M |
Operating Income | 856.51M | -302.57M | -439.5M | -447.41M | -374.44M | -431.77M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 696.62M | -363.12M | -696.11M | -587.49M | -518.34M | -402.93M |
Net Income | 682.64M | -363.3M | -626.6M | -559.02M | -523.9M | -438.16M |
Selling & General & Admin | 347.14M | 300.91M | 332.54M | 326M | 285.77M | 245.16M |
Research & Development | 455.25M | 534.48M | 666.56M | 651.5M | 540.68M | 477.64M |
Other Expenses | n/a | 216.56M | 312.74M | 124.04M | 54.25M | 70.79M |
Operating Expenses | 802.39M | 1.05B | 1.31B | 1.1B | 880.71M | 793.59M |
Interest Expense | 152.23M | 166.99M | 129.18M | 90.87M | 86.02M | 56.35M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 874.15M | 1.11B | 1.38B | 1.15B | 913.04M | 812.53M |
Income Tax Expense | 13.98M | 176K | -69.51M | -28.47M | 5.56M | 35.23M |
Shares Outstanding (Basic) | 79.53M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M |
Shares Outstanding (Diluted) | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M |
EPS (Basic) | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 |
EPS (Diluted) | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 |
EBITDA | 887.66M | -120.46M | -330.34M | -367.78M | -368.18M | -303.09M |
EBIT | 848.85M | -196.13M | -566.93M | -496.62M | -432.32M | -346.58M |
Depreciation & Amortization | 38.82M | 75.66M | 236.59M | 128.84M | 64.13M | 43.49M |
Add to Watchlist
Select watchlists to add or remove PTCT